These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26095193)

  • 81. Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research.
    Kwak S; Nishimoto Y; Yamashita T
    RNA Biol; 2008; 5(4):193-7. PubMed ID: 18971634
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity.
    Liu Y; Wolff KC; Jacobs BL; Samuel CE
    Virology; 2001 Oct; 289(2):378-87. PubMed ID: 11689059
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Editing of Cellular Self-RNAs by Adenosine Deaminase ADAR1 Suppresses Innate Immune Stress Responses.
    George CX; Ramaswami G; Li JB; Samuel CE
    J Biol Chem; 2016 Mar; 291(12):6158-68. PubMed ID: 26817845
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Changes in ADAR RNA editing patterns in CMV and ZIKV congenital infections.
    Wales-McGrath B; Mercer H; Piontkivska H
    BMC Genomics; 2023 Nov; 24(1):685. PubMed ID: 37968596
    [TBL] [Abstract][Full Text] [Related]  

  • 85. ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer.
    Cho CJ; Myung SJ; Chang S
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398248
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Adenosine deaminases acting on RNA, RNA editing, and interferon action.
    George CX; Gan Z; Liu Y; Samuel CE
    J Interferon Cytokine Res; 2011 Jan; 31(1):99-117. PubMed ID: 21182352
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A-to-I RNA editing as a tuner of noncoding RNAs in cancer.
    Liao Y; Jung SH; Kim T
    Cancer Lett; 2020 Dec; 494():88-93. PubMed ID: 32822814
    [TBL] [Abstract][Full Text] [Related]  

  • 88. ADAR RNA editing in innate immune response phasing, in circadian clocks and in sleep.
    Sinigaglia K; Wiatrek D; Khan A; Michalik D; Sambrani N; Sedmík J; Vukić D; O'Connell MA; Keegan LP
    Biochim Biophys Acta Gene Regul Mech; 2019 Mar; 1862(3):356-369. PubMed ID: 30391332
    [TBL] [Abstract][Full Text] [Related]  

  • 89. AKT-Dependent Phosphorylation of ADAR1p110 and ADAR2 Represents a New and Important Link Between Cell Signaling and RNA Editing.
    Piazzi M; Bavelloni A; Gallo A; Blalock WL
    DNA Cell Biol; 2020 Mar; 39(3):343-348. PubMed ID: 31999481
    [TBL] [Abstract][Full Text] [Related]  

  • 90. RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions.
    Valente L; Nishikura K
    J Biol Chem; 2007 Jun; 282(22):16054-61. PubMed ID: 17428802
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Identification of substrates for adenosine deaminases that act on RNA.
    Morse DP
    Methods Mol Biol; 2004; 265():199-218. PubMed ID: 15103075
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Modulation of RNA editing by functional nucleolar sequestration of ADAR2.
    Sansam CL; Wells KS; Emeson RB
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14018-23. PubMed ID: 14612560
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Accumulation of nuclear ADAR2 regulates adenosine-to-inosine RNA editing during neuronal development.
    Behm M; Wahlstedt H; Widmark A; Eriksson M; Öhman M
    J Cell Sci; 2017 Feb; 130(4):745-753. PubMed ID: 28082424
    [TBL] [Abstract][Full Text] [Related]  

  • 94. ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.
    Sakata KI; Maeda K; Sakurai N; Liang S; Nakazawa S; Yanagihara K; Kubo T; Yoshiyama H; Kitagawa Y; Hamada JI; Iizasa H
    Anticancer Res; 2020 Mar; 40(3):1307-1314. PubMed ID: 32132027
    [TBL] [Abstract][Full Text] [Related]  

  • 95. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1).
    George CX; John L; Samuel CE
    J Interferon Cytokine Res; 2014 Jun; 34(6):437-46. PubMed ID: 24905200
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Glutamate receptor RNA editing: a molecular analysis of GluR2, GluR5 and GluR6 in human brain tissues and in NT2 cells following in vitro neural differentiation.
    Barbon A; Vallini I; La Via L; Marchina E; Barlati S
    Brain Res Mol Brain Res; 2003 Oct; 117(2):168-78. PubMed ID: 14559151
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Engineered alterations in RNA editing modulate complex behavior in Drosophila: regulatory diversity of adenosine deaminase acting on RNA (ADAR) targets.
    Jepson JEC; Savva YA; Yokose C; Sugden AU; Sahin A; Reenan RA
    J Biol Chem; 2011 Mar; 286(10):8325-8337. PubMed ID: 21078670
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Deamination of mammalian glutamate receptor RNA by Xenopus dsRNA adenosine deaminase: similarities to in vivo RNA editing.
    Hurst SR; Hough RF; Aruscavage PJ; Bass BL
    RNA; 1995 Dec; 1(10):1051-60. PubMed ID: 8595560
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.
    Qin YR; Qiao JJ; Chan TH; Zhu YH; Li FF; Liu H; Fei J; Li Y; Guan XY; Chen L
    Cancer Res; 2014 Feb; 74(3):840-51. PubMed ID: 24302582
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity.
    Katrekar D; Xiang Y; Palmer N; Saha A; Meluzzi D; Mali P
    Elife; 2022 Jan; 11():. PubMed ID: 35044296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.